blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2914255

EP2914255 - TREATMENT OR PREVENTION OF CARDIOVASCULAR EVENTS VIA THE ADMINISTRATION OF COLCHICINE [Right-click to bookmark this link]
Former [2015/37]TREATMENT OR PREVENTION OF CARDIOVASCULAR EVENTS VIA THE ADMINISTRATION OF A COLCHICINE DERIVATIVE
[2021/29]
StatusThe patent has been granted
Status updated on  18.06.2021
Database last updated on 19.10.2024
FormerGrant of patent is intended
Status updated on  18.01.2021
FormerExamination is in progress
Status updated on  30.11.2020
FormerGrant of patent is intended
Status updated on  15.11.2020
FormerExamination is in progress
Status updated on  13.07.2018
Most recent event   Tooltip01.10.2024Change: Date of oral proceedings 
01.10.2024Deletion: Despatch of minutes of oral proceedings 
Applicant(s)For all designated states
Murray & Poole Enterprises, Ltd.
Suite 41/42
Victoria House
26 Main Street
Gibraltar / GB
[2021/29]
Former [2015/37]For all designated states
Murray & Poole Enterprises, Ltd.
Suite 41/42
Victoria House
26 Main Street
Gibraltar / GB
Inventor(s)01 / NIDORF, Mark
32 Melrose Crescent
Menora, Western Australia 6050 / AU
 [2015/37]
Representative(s)Cohausz & Florack
Patent- & Rechtsanwälte
Partnerschaftsgesellschaft mbB
Postfach 10 18 30
40009 Düsseldorf / DE
[N/P]
Former [2021/29]Hutter, Anton
Venner Shipley LLP
5 Stirling House
Stirling Road The Surrey Research Park
Guildford GU2 7RF / GB
Former [2015/37]Silcock, Peter James
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date13851803.001.11.2013
[2015/37]
WO2013AU01261
Priority number, dateAU2012090482802.11.2012         Original published format: AU 2012904828
AU2012090486805.11.2012         Original published format: AU 2012904868
[2015/37]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014066944
Date:08.05.2014
Language:EN
[2014/19]
Type: A1 Application with search report 
No.:EP2914255
Date:09.09.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 08.05.2014 takes the place of the publication of the European patent application.
[2015/37]
Type: B1 Patent specification 
No.:EP2914255
Date:21.07.2021
Language:EN
[2021/29]
Search report(s)International search report - published on:AU08.05.2014
(Supplementary) European search report - dispatched on:EP30.05.2016
ClassificationIPC:A61K31/165, A61K31/122, A61P9/10, A61K45/06, A61K31/37, A61K31/4365
[2016/26]
CPC:
A61K31/165 (EP,EA,KR,US); A61K45/06 (EP,EA,KR,US); A61K31/37 (EA,US);
A61K31/40 (KR); A61K31/4365 (EA,KR,US); A61K31/616 (EP,EA,KR,US);
A61P29/00 (EP); A61P9/10 (EP,KR); A61K2300/00 (KR) (-)
C-Set:
A61K31/165, A61K2300/00 (EP,US);
A61K31/616, A61K2300/00 (US,EP)
Former IPC [2015/37]A61K31/165, A61K31/122, A61P9/10
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/37]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:BEHANDLUNG ODER VORBEUGUNG VON KARDIOVASKULÄREN EREIGNISSEN DURCH DIE GABE VON COLCHICIN[2021/29]
English:TREATMENT OR PREVENTION OF CARDIOVASCULAR EVENTS VIA THE ADMINISTRATION OF COLCHICINE[2021/29]
French:TRAITEMENT OU PRÉVENTION DES ÉVÉNEMENTS CARDIOVASCULAIRES VIA L' ADMINISTRATION DE COLCHICINE[2021/29]
Former [2015/37]BEHANDLUNG ODER VORBEUGUNG VON KARDIOVASKULÄREN EREIGNISSEN DURCH VERABREICHUNG EINES COLCHICINDERIVATS
Former [2015/37]TREATMENT OR PREVENTION OF CARDIOVASCULAR EVENTS VIA THE ADMINISTRATION OF A COLCHICINE DERIVATIVE
Former [2015/37]TRAITEMENT OU PRÉVENTION D'ÉVÉNEMENTS CARDIOVASCULAIRES PAR ADMINISTRATION D'UN DÉRIVÉ DE COLCHICINE
Entry into regional phase21.05.2015National basic fee paid 
21.05.2015Search fee paid 
21.05.2015Designation fee(s) paid 
21.05.2015Examination fee paid 
Examination procedure21.05.2015Examination requested  [2015/37]
21.12.2016Amendment by applicant (claims and/or description)
11.07.2018Despatch of a communication from the examining division (Time limit: M04)
20.11.2018Reply to a communication from the examining division
09.04.2019Despatch of a communication from the examining division (Time limit: M02)
07.06.2019Reply to a communication from the examining division
31.01.2020Despatch of a communication from the examining division (Time limit: M04)
18.05.2020Reply to a communication from the examining division
16.11.2020Communication of intention to grant the patent
25.11.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
19.01.2021Communication of intention to grant the patent
25.05.2021Fee for grant paid
25.05.2021Fee for publishing/printing paid
25.05.2021Receipt of the translation of the claim(s)
Divisional application(s)EP21185610.9  / EP3964205
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  11.07.2018
Opposition(s)Opponent(s)01  20.04.2022  22.04.2022  ADMISSIBLE
Pharmascience Inc.
6111, av. Royalmount
Montréal, Québec H4P 2T4 / CA
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 02  21.04.2022  25.04.2022  ADMISSIBLE
Teva Nederland B.V.
Swensweg 5
2031 GA Haarlem / NL
Opponent's representative
D Young & Co LLP
3 Noble Street
London EC2V 7BQ / GB
 [N/P]
Former [2022/22]
Opponent(s)01  20.04.2022  22.04.2022  ADMISSIBLE
Pharmascience Inc.
6111, av. Royalmount
Montréal, Québec H4P 2T4 / CA
Opponent's representative
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 02  21.04.2022  25.04.2022  ADMISSIBLE
Teva Nederland B.V.
Swensweg 5
2031 GA Haarlem / NL
Opponent's representative
D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Former [2022/21]
Opponent(s)01  20.04.2022   
Pharmascience Inc.
6111, av. Royalmount
Montréal, Québec H4P 2T4 / CA
Opponent's representative
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
09.05.2022Invitation to proprietor to file observations on the notice of opposition
19.09.2022Reply of patent proprietor to notice(s) of opposition
26.09.2023Date of oral proceedings
20.10.2023Despatch of interlocutory decision in opposition
20.10.2023Despatch of minutes of oral proceedings
Appeal following opposition28.12.2023Appeal received No.  T2037/23
28.12.2023Payment of appeal fee
29.02.2024Statement of grounds filed
22.12.2023Appeal received No.  T2037/23
22.12.2023Payment of appeal fee
29.02.2024Statement of grounds filed
19.12.2023Appeal received No.  T2037/23
19.12.2023Payment of appeal fee
27.02.2024Statement of grounds filed
23.10.2025Date of oral proceedings
Fees paidRenewal fee
27.11.2015Renewal fee patent year 03
10.11.2016Renewal fee patent year 04
13.11.2017Renewal fee patent year 05
14.11.2018Renewal fee patent year 06
14.11.2019Renewal fee patent year 07
13.11.2020Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL21.07.2021
CY21.07.2021
MC21.07.2021
MK21.07.2021
MT21.07.2021
RO21.07.2021
RS21.07.2021
SM21.07.2021
BG21.10.2021
GR22.10.2021
LU01.11.2021
[2024/41]
Former [2024/22]AL21.07.2021
CY21.07.2021
MC21.07.2021
MK21.07.2021
RO21.07.2021
RS21.07.2021
SM21.07.2021
BG21.10.2021
GR22.10.2021
LU01.11.2021
Former [2023/30]AL21.07.2021
CY21.07.2021
MC21.07.2021
RO21.07.2021
RS21.07.2021
SM21.07.2021
BG21.10.2021
GR22.10.2021
LU01.11.2021
Former [2022/34]AL21.07.2021
MC21.07.2021
RO21.07.2021
RS21.07.2021
SM21.07.2021
BG21.10.2021
GR22.10.2021
LU01.11.2021
Former [2022/33]AL21.07.2021
MC21.07.2021
RO21.07.2021
RS21.07.2021
SM21.07.2021
BG21.10.2021
GR22.10.2021
Former [2022/29]AL21.07.2021
RO21.07.2021
RS21.07.2021
SM21.07.2021
BG21.10.2021
GR22.10.2021
Former [2022/26]RO21.07.2021
RS21.07.2021
SM21.07.2021
BG21.10.2021
GR22.10.2021
Former [2022/12]RS21.07.2021
BG21.10.2021
GR22.10.2021
Former [2022/09]RS21.07.2021
BG21.10.2021
Documents cited:Search[XY]WO9215282  (INDIANA UNIVERSITY FOUNDATION [US]);
 [XY]CN1939290  (LU XIANGUANG [CN]);
International search[X]US2006286108  (BELL KATHERINE A [US]);
 [X]WO2007048004  (CORNELL RES FOUNDATION INC [US], et al);
 [X]WO2008131192  (UNIV COLUMBIA [US], et al);
 [X]WO2010046628  (UNIV BRADFORD [GB], et al);
 [X]US2011190397  (DAVIS MATTHEW W [US])
by applicantEP2128170
 US2009312430
 WO2010138670
 WO2011022805
 US2011178180
OppositionWO2014066944
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.